Identification of pharmacokinetically stable 3,10-dibromo-8- chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities

Journal of Medicinal Chemistry

Volumn 42, Issue 14, 1999, Pages 2651-2661

  Taveras, Arthur G ^a   Deskus, Jeff ^a   Chao, Jianping ^a   Vaccaro, Cynthia J ^a   Njoroge, F George ^a   Vibulbhan, Bancha ^a   Pinto, Pat ^a   Remiszewski, Stacy ^a   Del Rosario, Jocelyn ^a   Doll, Ronald J ^a   Alvarez, Carmen ^a   Lalwani, Tarik ^a   Mallams, Alan K ^a   Rossman, Randall R ^a   Afonso, Adriano ^a   Girijavallabhan, Viyyoor M ^a   Ganguly, Ashit K ^a   Pramanik, Birendra ^a   Heimark, Larry ^a   Bishop, W Robert ^a   Wang, Lynn ^a   Kirschmeier, Paul ^a   James, Linda ^a   Carr, Donna ^a   Patton, Robert ^a   Bryant, Mathew S ^a   Nomeir, Amin A ^a   Liu, Ming ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [4 [3,10 DIBROMO 8 CHLORO 6,11 DIHYDRO 5H BENZO(5,6) CYCLOHEPTA[1,2 B]PYRIDIN 11 YL] 1 PIPERIDINYL] 2 OXOETHYL] 1 PIPERIDINECARBOXAMIDE; ACETAMIDE; NICOTINAMIDE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P21; SULFONAMIDE; SULFONYLUREA DERIVATIVE; TRIHALOBENZOCYCLOHEPTAPYRIDINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CELL MATURATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ONCOGENE RAS; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ALKYL AND ARYL TRANSFERASES; ANIMALS; BIOLOGICAL AVAILABILITY; CELL DIVISION; COS CELLS; ENZYME INHIBITORS; HAPLORHINI; MICE; MICE, NUDE; PIPERIDINES; PROTEIN ISOPRENYLATION; PROTO-ONCOGENE PROTEINS P21(RAS); PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; SULFONYLUREA COMPOUNDS;

EID: 0033566167     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990059k     Document Type: Article

References (34)

1. (a) Barbacid, M. ras Genes. Annu. Rev. Biochem. 1987, 56, 779-827.
2. (b) Der, C.; Cox, A. D. Isoprenoid Modification and Plasma Membrane Association: Critical Factors for Ras Oncogenicity. Cancer Cells 1991, 3, 331-340.
3. (c) Willumsen, B. M.; Norris, K.; Papageorge, A. G.; Hubbert, N. L.; Lowry, D. R. Harvey Murine Sarcoma Virus p21 Ras Protein: Biological and Biochemical Significance of the Cysteine Nearest the Carboxyl Terminus. EMBO J. 1984, 3, 2581-2585.
4. (d) Lowry, D. R.; Willumsen, B. M. New Clue to the Ras Lipid Glue. Nature (London) 1989, 341, 384-385.
5. (e) Gibbs, J. B. Cell 1991, 65, 1-4.
6. (f) Khosravi-Far, R.; Cox, A. D.; Kato, K.; Der, C. J. Cell Growth Differen. 1992, 3, 461-469.
7. Barbacid, M. Eur. J. Clin. Invest. 1990, 20, 225-235.
8. Casey, P. J.; Solski, P. A.; Der, C. I.; Buss, J. E. p21 Ras is Modified by a Farnesyl Isoprenoid. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 8323-8327.
9. (a) Reiss, Y.; Goldstein, J. L.; Seabra, M. C.; Casey, P. J.; Brown, M. S. Cell 1990, 62, 81-88.
10. (b) Hancock, J. F.; Magee, A. I.; Childs, J. E.; Marshall, C. J. Cell 1989, 57, 1176-77.
11. (a) James, G. L.; Goldstein, J. L.; Brown, M. S.; Rawson, T. E.; Somers, T. C.; McDowell, R. S.; Crowley, C.; Lucas, B.; Levinson, A.; Masters, J. C. Science 1993, 260, 1937-1942.
12. (b) Kohl, N. E.; Mosser, S. D.; DeSolms, J.; Giuliani, E. A.; Pompliano, D. L.; Graham, S. L.; Smith, R. L.; Scolnick, E. M.; Oliff, A.; Gibbs, J. B. Science 1993, 260, 1934-1937.
13. (c) Garcia, A. M.; Rowell, C.; Ackermann, K.; Kowalczyk, J. J.; Lewis, M. D. J. Biol. Chem. 1993, 268, 18415-18418.
14. (d) Vogt, A.; Qian, Y.; Blaskovich, M. A.; Fossum, R. D.; Hamilton, A. D.; Sebti, S. M. J. Biol. Chem. 1995, 270, 660-664.
15. (e) Kohl, N. E.; Wilson, F. R.; Mosser, S. D.; Giuliani, E.; DeSolms, S. J.; Conner, M. W.; Anthony, N. J.; Holtz, W. J.; Gomez, R. P.; Lee, T.-J.; Smith, R. L.; Graham, S. L.; Hartman, G. D.; Gibbs, J. B.; Oliff, A. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 9141-9145.
16. (a) Gibbs, J. B. Ras C-Terminal Processing Enzyme-New Drug Targets. Cell 1991, 65, 1-4.
17. (b) Gibbs, J. B.; Oliff, A.; Kohl, N. Farnesyltransferase Inhibitors: Ras Research Yields a Potential Cancer Therapeutics. Cell 1994, 77, 175-178.
18. (c) Graham, S. L Inhibitors of Protein Farnesylation: A New Approach to Cancer Chemotherapy. Exp. Opin. Ther. Patents 1995, 5, 1269-1285.
19. (d) Leonard, D. M. Ras Farnesyltransferase: a New Therapeutic Target. J. Med. Chem. 1997, 40, 2971-2990.
20. (e) McNamara, D. J.; Dobrusin, E.; Leonard, D. M.; Shuler, K. R.; Katltenbronn, J. S.; Quinnll, J.; Bur, S.; Thomas, C. E.; Doherty, A. M.; Scholten, J. D.; Zimmerman, K. K.; Gibbs, B. S.; Gowan, R. C.; Latash, M. P. J. Med. Chem. 1997, 40, 3319-3322.
21. (f) Leftheris, K.; Kline, T.; Vite, G. D.; Cho, Y. H.; Bhide, R. S.; Patel, D. V.; Patel, M. M.; Schmidt, R. J.; Weller, H. N.; Andahazy, M. L.; Carboni, J. M.; Gullo-Brown, J. L.; Lee, F. Y. F.; Ricca, C.; Rose, W. C.; Yan, N.; Barbacid, M.; Hunt, J. T.; Meyers, C. A.; Seizinger, B. R.; Zahler, R.; Manne, V. Development of Highly Potent Inhibitors of Ras Farnesyltransferase Possessing Cellular and in Vivo Activity. J. Med. Chem. 1996, 39, 224-236.
22. (a) Bishop, W. R.; Bond, R.; Petrin, J.; Wang, L.; Patton, R.; Doll, R.; Njoroge, N.; Windsor, W.; Syto, R.; Schwartz, J.; Carr, D.; James, L.; Kirschmeier, P. J. Biol. Chem. 1995, 270, 30611-30618.
23. (b) Mallams, A. K.; Njoroge, F. G.; Doll, R. J.; Snow, M. E.; Kaminski, J. J.; Rossman, R.; Vibulbhan, B.; Bishop, W. R.; Kirschmeier, P.; Liu, M.; Bryant, M. S.; Alvarez, C.; Carr, D.; James, L.; King, I.; Li, Z.; Lin, C.-C.; Nardo, C.; Petrin, J.; Remiszewski, S.; Taveras, A.; Wang, S.; Wong, J.; Catino, J.; Girijavallabhan, V.; Ganguly, A. K. Bioorg. Med. Chem. 1997, 5, 93-99.
24. (c) Njoroge, F. G.; Doll, R. J.; Vibulbhan, B.; Alvarez, C.; Bishop, W. R.; Petrin, J.; Kirschmeier, P.; Carruthers, N. I.; Wong, J. K.; Albanese, M. M.; Piwinski, J. J.; Catino, J.; Girijavallabhan, V.; Ganguly, A. K. Bioorg. Med. Chem. 1997, 5, 101-114.
25. (d) Njoroge, F. G.; Vibulbhan, B.; Rane, D. F.; Bishop, W. R.; Petrin, J.; Patton, R.; Bryant, M. S.; Chen, K.-J.; Nomeir, A. A.; Lin, C.-C.; Liu, M.; King, I.; Chen, J.; Lee, S.; Yaremko, B.; Dell, J.; Lipari, P.; Malkowski, M.; Li, Z.; Catino, J.; Doll, R. J.; Girijavallabhan, V.; Ganguly, A. K. Structure-Activity Relationship of 3-Substituted N-Pyridinylacetyl-4-(8-chloro-5,6-dihydro-11H-benzo[5,6-]cyclohepta[1,2-b] pyridinyl-11-ylidene)piperidine Inhibitors of Farnesyl-Protein Transferase: Design and Synthesis of in Vivo Active Antitumor Compounds. J. Med. Chem. 1997, 40, 4290-4301.
26. (a) Njoroge, F. G.; Taveras, A. G.; Kelly, J.; Remiszewski, S. W.; Mallams, A. K.; Wolin, R.; Afonso, A.; Cooper, A. B.; Rane, D.; Liu, Y.-T.; Wong, J.; Vibulbhan, B.; Pinto, P.; Deskus, J.; Alvarez, C.; Del Rosario, J.; Connolly, M.; Wang, J.; Desai, J. A.; Rossman, R. R.; Bishop, W. R.; Patton, R.; Wang, L.; Kirschmeier, P.; Bryant, M. S.; Nomeir, A. A.; Lin, C.-C.; Liu, M.; McPhail, A. T.; Doll, R. J.; Girijavallabhan, V.; Ganguly, A. K. (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta-[1,2-b] pyridin-11(R)-yl)-1-piperidinyl]-2-oxoethyl]-1-piperidine-carboxamide (Sch-66336): A Very Potent Farnesyl Protein Transferase Inhibitor as a Novel Antitumor Agent. J. Med. Chem. 1998, 41, 4890.
27. (b) Liu, M.; Bryant, M. S.; Chen, J.; Lee, S.; Yaremko, B.; Lipari, P.; Malkowski, M.; Ferrari, E.; Nielsen, L.; Prioloi, N.; Dell, J.; Sinha, D.; Syed, J.; Korfmacher, W. A.; Nomeir, A. A.; Lin, C.-C.; Wang, L.; Taveras, A. G.; Doll, R. J.; Njoroge, G.; Mallams, A. K.; Remiszewski, S.; Catino, J. J.; Girijavallabhan, V. M.; Kirschmeier, P.; Bishop, W. R. Antitumor Activity of Sch-66336, an Orally Bioavailable Tricyclic Inhibitor of Farnesyl Protein Transferase, in Human Tumor Xenograft Models and Wap-ras Transgenic Mice. Cancer Res. 1998, 58, 4947-4956.
28. Njoroge, F. G.; Taveras, A. G.; Kelly, S.; Remiszewski, S. W.; Mallams, A. K; Doll, R. J.; Girijavallabhan, V.; Afonso, A.; Wohn, R.; Alvarez, C.; Cesarz, D.; Connolly, M.; Cooper, A. B.; Del Rosario, J.; Desai, J. A.; Deskus, J.; Dritz, J.; Hollinger, F.; Kiminski, J. J.; Liu, Y.-T.; Pinto, P.; Rane, D.; Rossman, R. R.; Saksena, A. K.; Snow, M. E.; Vibulbhan, B.; Wang, J.; Ganguly, A. K.; Bishop, W. R.; Kirschmeier, P.; Carr, D.; James, L.; Patton, R.; Bryant, M. S.; Nomeir, A. A.; Liu, M.; Wang, S.; Nardo, C.; Kumari, P.; Chen, K.-J.; Watkins, R.; Korfmacher, W. A.; Lin, C.-C. Orally Active, Trihalobenzocycloheptapyridine Farnesyl Protein TransferaseInhibitor Antitumor Agents. Presentation at the 8th American Association for Cancer Research Meeting, New Orleans, LA, March 28-April 1, 1998.
29. (a) Appel, R.; Berger, G. Chem. Ber. 1958, 91, 1339-1341.
30. (b) Atkins, G. M., Jr.; Burgess, E. M. J. Am. Chem. Soc. 1967, 89, 2502-2503.
31. Bryant, M. S.; Korfmacher, W. A.; Wang, S.; Nardo, C.; Nomeir, A. A.; Lin, C.-C. Pharmacokinetic Screening for Selection of New Drug Discovery Candidates is Greatly Enhanced Through the Use of Liquid Chromatography-Atmospheric Pressure Ionization Tandem Mass Spectrometry. J. Chromatogr. 1997, 777, 61-66.
32. For similar modifications made to dihalobenzocycloheptapyridines, see: Mallams, A. K.; Rossman, R. R.; Doll, R. J.; Girijavallabhan, V. M.; Ganguly, A. K.; Petrin, J.; Wang, L.; Patton, R.; Bishop, W. R.; Carr, D. M.; Kirschmeier, P.; Catino, J. J.; Bryant, M. S.; Chen, K.-J.; Korfmacher, W. A.; Nardo, C.; Wang, S.; Nomeir, A. A.; Lin, C.-C.; Li, Z.; Chen, J.; Lee, S.; Dell, J.; Lipari, P.; Malkowski, M.; Yaremko, B.; King, I.; Liu, M. Inhibitors of Farnesyl Protein Transferase, 4-Amido, 4-Carbamoyl, and 4-Carboxamido Derivatives of 1-(8-Chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl) piperazine. J. Med. Chem. 1998, 41, 877-893.
33. Coppa, F.; Fontana, F.; Lazzarini, E.; Minisci, F. A facile, convenient and selective homolytic carbamoylation of heteroaromatic bases. Heterocycles 1993, 36, 2687-2696.
34. Unpublished observations during pharmacokinetic analysis of experimental compounds at Schering-Plough.